Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

Epidermolysis Bullosa Dystrophica, Recessive clinical trials

1 of 1 indexed Epidermolysis Bullosa Dystrophica, Recessive trials are currently recruiting.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Epidermolysis Bullosa Dystrophica, Recessive: 1 US clinical trial tracked, 1 recruiting.

Epidermolysis Bullosa Dystrophica, Recessive is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is Krystal Biotech, running 1 of these trials.

Enrollment posture brief

Registry condition epidermolysis-bullosa-dystrophica-recessive

OPEN 1 | RECR 100% | LATE 0 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Epidermolysis Bullosa Dy (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Epidermolysis Bullosa Dystrophica, Recessive

Epidermolysis Bullosa Dystrophica, Recessive lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Epidermolysis Bullosa Dystrophica, Recessive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Epidermolysis Bullosa Dystrophica, Recessive is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Top Sponsors

Krystal Biotech 1 trials

US sites by state

Facility locations filed on Epidermolysis Bullosa Dystrophica, Recessive trials. A trial with sites in several states counts in each.

Pennsylvania 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Epidermolysis Bullosa Dystrophica, Recessive page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Epidermolysis Bullosa Dystrophica, Recessive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Krystal Biotech sponsors the most Epidermolysis Bullosa Dystrophica, Recessive trials on record, review their full trial history before evaluating a specific study. See Krystal Biotech's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epidermolysis Bullosa Dystrophica, Recessive condition card totals 1 registered trials; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.